MIM
ADMS

MetLife Investment Management’s Adamas Pharmaceuticals ADMS Stock Holding History

MetLife Investment Management’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-10,769
Closed -$216K – 2612
2018
Q3 		$216K Hold
10,769
– – ﹤0.01% 2035
2018
Q2 		$278K Buy
10,769
+3,729
+53% +$103K ﹤0.01% 1750
2018
Q1 		$168K Hold
7,040
– – ﹤0.01% 1985
2017
Q4 		$239K Buy
+7,040
New +$197K ﹤0.01% 1835

Other funds holding ADMS

Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return

MetLife Investment Management's ADMS Position: Q4 2018 in Review

MetLife Investment Management sold out of Adamas Pharmaceuticals (ADMS) in Q4 2018, closing a stake of 10,769 shares — an estimated $216K sold.

MetLife Investment Management first reported a position in ADMS in Q4 2017 and held it in 4 quarters. The position peaked at $278K in Q2 2018. 98 funds tracked by Wall St. Rank hold ADMS as of Q4 2018.

  • MetLife Investment Management reported no remaining Adamas Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • MetLife Investment Management sold 10,769 Adamas Pharmaceuticals shares in Q4 2018, an estimated $216K.
  • MetLife Investment Management first reported a position in Adamas Pharmaceuticals in Q4 2017 and held it in 4 quarters.
  • MetLife Investment Management's Adamas Pharmaceuticals position peaked at $278K in Q2 2018.
  • 98 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2018.

Based on MetLife Investment Management's 13F filing for Q4 2018, filed 14 Feb 2019.